Tscan Therapeutics Inc
NASDAQ:TCRX 11:22:42 AM EDT
| Market Cap (Intraday) | 312.81M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $7.18 |
| 50-Day MA | $7.08 |
| 200-Day MA | $4.69 |
Tscan Therapeutics Inc Stock, NASDAQ:TCRX
830 Winter Street, Waltham, Massachusetts 02451
United States of America
Phone: +1.857.399.9500
Number of Employees: 154
Description
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.